DDInter1066 DDInter1822
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L
Aminoglycosides, many of which are derived directly from _Streptomyces_ spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic _Pseudomonas aeruginosa_ infections in cystic fibrosis patients, as _P. aeruginosa_ is notoriously inherently resistant to many antibiotics.[A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.[L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.[A232294, A232349, L32739, L32749] Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).[L32739, L32744, L32749]
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Lidocaine {u} (Compound) causes {v} (Side Effect) Apnoea
Apnoea {u} (Side Effect) is caused by {v} (Compound) Tobramycin
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Paromomycin
Paromomycin {u} (Compound) resembles {v} (Compound) Tobramycin
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gentamicin
Gentamicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Neomycin
Neomycin {u} (Compound) resembles {v} (Compound) Paromomycin
Paromomycin {u} (Compound) resembles {v} (Compound) Tobramycin
Lidocaine {u} (Compound) causes {v} (Side Effect) Apnoea
Apnoea {u} (Side Effect) is caused by {v} (Compound) Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Gentamicin {u} (Compound) resembles {v} (Compound) Tobramycin
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gentamicin
Gentamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neomycin
Neomycin {u} (Compound) resembles {v} (Compound) Tobramycin
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nadolol
Nadolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Neomycin
Neomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Gentamicin {u} (Compound) resembles {v} (Compound) Tobramycin
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Kanamycin and Kanamycin (Compound) resembles Tobramycin (Compound)
Lidocaine (Compound) causes Apnoea (Side Effect) and Apnoea (Side Effect) is caused by Tobramycin (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Kanamycin and Kanamycin (Compound) resembles Paromomycin (Compound) and Paromomycin (Compound) resembles Tobramycin (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Gentamicin and Gentamicin (Compound) resembles Kanamycin (Compound) and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Tobramycin (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Neomycin and Neomycin (Compound) resembles Paromomycin (Compound) and Paromomycin (Compound) resembles Tobramycin (Compound)
Lidocaine (Compound) causes Apnoea (Side Effect) and Apnoea (Side Effect) is caused by Kanamycin (Compound) and Kanamycin (Compound) resembles Tobramycin (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Kanamycin and Kanamycin (Compound) resembles Gentamicin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin (Compound) resembles Tobramycin (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin (Compound) resembles Tobramycin (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol may cause a minor interaction that can limit clinical effects when taken with Kanamycin and Kanamycin (Compound) resembles Tobramycin (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin (Compound) resembles Tobramycin (Compound)